L'oreal

Agnes Thomas-Collignon

Dominique Bernard

Benoit Muller

Roger Rozot

The present invention relates to the use of a compound, suitable for modulating the interaction between first and second partner proteins, or between homologues, mutants, or fragments of said proteins, said first and second proteins being SASPase and filaggrin-2, or FLG2, as an active agent for treating and/or preventing aesthetic defects in the skin, and/or in the appendages thereof, linked to an imbalance in the differentiation and/or proliferation of the cells of the epidermis.

Process for treating an individual with an esthetic defect of skin by modulating SASPase FLG2 complex

An isolated peptide from skin aspartic protease (SASPase) or filaggrin-2 (FLG2), a fragment or homologue thereof, which can modify the three-dimensional shape of a complex formed by interaction between a first amino acid sequence from filaggrin-2 and a second amino acid sequence from SASPase, is described. The isolated peptide is useful as a target for screening for cosmetic or therapeutic active agents with regard to the skin and/or its appendages.

Growing community of inventors

Montigny le Bretonneux, France

Agnes Thomas-Collignon